share_log

HC Wainwright & Co. Downgrades TherapeuticsMD to Neutral, Announces $10 Price Target

HC Wainwright & Co. Downgrades TherapeuticsMD to Neutral, Announces $10 Price Target

HC Wainwright & Co.將TherapeuticSMD的評級下調至中性,宣佈10美元的目標股價
Benzinga Real-time News ·  2022/06/07 07:24

HC Wainwright & Co. analyst Douglas Tsao downgrades TherapeuticsMD (NASDAQ:TXMD) from Buy to Neutral and announces $10 price target.

HC Wainwright&Co.分析師Douglas Tsao將TreateuticsMD(納斯達克代碼:TXMD)的評級從買入下調至中性,並宣佈目標價10美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論